Ireland· IE-PA-EU/1/24/1901/001-003
Nemluvio 30 mg powder and solvent for solution for injection in pre-filled pen
A nemolizumab product containing nemolizumab, registered in Ireland by Galderma International. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Nemolizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AH12 (nemolizumab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Nemolizumab · ATC D11AH12
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nemolizumab costs, country by country.
Normalised to the WHO defined daily dose (0.8 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nemolizumab · price per daily dose (0.8 mg)
USD · FX 28 Sept 2026
- CH Switzerland$67.16
The record
At a glance
HPRA (Ireland)- Active substance
- Nemolizumab
- Manufacturer
- Galderma International
- Country
- Ireland (IE)
- ATC code
- D11AH12
- ATC class
- Nemolizumab
- Defined daily dose
- 0.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/24/1901/001-003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nemolizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceNEMLUVIO 30 mg, poudre et solvant pour solution injectable en stylo prérempliGALDERMA INTERNATIONAL
- NetherlandsNemluvio 30 mg poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde penGalderma International
- CzechiaNEMLUVIOGalderma International, La Défense
- Japanネモリズマブ(遺伝子組換え)マルホ
- SwitzerlandNemluvio 30 mg, Pulver und Lösungsmittel für Injektionslösung im FertigpenGalderma SA
- PolandNemluvioGalderma International
- SwedenNemluvio 30 mg Pulver och vätska till injektionsvätska, lösning i förfylld injektionspennaGalderma International
- BelgiumNemluvio 30 mgGalderma International
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nemluvio
- Liechtenstein · Nemluvio
- Norway · Nemluvio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/91c0edf3-a029-47fd-bd88-5f68b547fe04 GET /v1/drugs/91c0edf3-a029-47fd-bd88-5f68b547fe04?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection in pre-filled pen",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"D11AH12"
],
"strength": null,
"pa_number": "EU/1/24/1901/001-003",
"substances": [
"Nemolizumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "12/02/2025",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about nemolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.